Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Floor J Backes, Dr Mansoor Raza Mirza, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Brian M Slomovitz, with cases presented by Dr Eric H Lee, Dr Priya Rudolph and Dr Lyndsay J Willmott, moderated by Dr Secord, including the following topics:
Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Salani
Introduction (0:00) Case: A woman in her mid 60s with dementia who has peritoneal carcinomatosis with OC — Eric H Lee, MD, PhD (3:00) Case: A woman in her mid 40s with advanced OC undergoes immediate cytoreduction — Lyndsay J Willmott, MD (9:52) Current Management of Relapsed/Refractory (R/R) OC; Promising Novel Agents and Strategies Under Investigation — Dr Backes
Case: A woman in her late 40s with a BRCA2 germline mutation and high-grade serous OC — Priya Rudolph, MD, PhD (26:44) Case: A woman in her mid 50s with platinum-sensitive recurrent OC who had not received a prior PARP inhibitor — Dr Willmott (33:35) First-Line Therapy for Advanced Endometrial Cancer (EC) — Dr Mirza
Case: A woman in her early 60s diagnosed with endometrioid cancer presents with abdominal pain 2 years later — Dr Rudolph (49:44) Case: A woman in her early 70s with microsatellite instability-high, mismatch repair-deficient Stage IV carcinosarcoma — Dr Willmott (56:44) Current Therapeutic Options for R/R EC; Novel Investigational Strategies — Dr Slomovitz
Case: A woman in her early 60s with a history of serous endometrial cancer (EC) presents with recurrent disease 2 years later — Dr Rudolph (1:12:44) Case: A woman in her late 70s with EC develops a cough 2 years after initial treatment — Dr Lee (1:19:50) Role of HER2-Targeted Therapy in the Management of Advanced OC, EC and Other Gynecologic Cancers — Dr Secord
Case: A woman in her late 60s with endometrioid adenocarcinoma is admitted with abdominal distention — Dr Rudolph (1:34:55) Case: A woman in her mid 30s with mucinous adenocarcinoma of the ovary is later diagnosed with a liver metastasis — Dr Lee (1:41:02) CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics:
Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22) The Incidence and Management of Interstitial Lung Disease with ADCs (34:05) ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02) ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53) NCPD information and select publications

Featuring perspectives from Dr Robin K (Katie) Kelley, Dr Edward Kim and Prof Arndt Vogel, and moderated by Dr Kelley, including the following topics:
Introduction (0:00) Recent Developments in the Management of Early- and Intermediate-Stage Hepatocellular Carcinoma (HCC) — Dr Kim (1:58) First-Line Therapy for Advanced HCC and Biliary Tract Cancers (BTCs) — Prof Vogel (22:24) Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Kelley (42:19) CME information and select publications

Featuring perspectives from Dr Jonathan W Goldman, Dr Corey J Langer, Dr Joel W Neal, Dr Zofia Piotrowska, Dr Joshua K Sabari and Dr Helena Yu, moderated by Dr Yu, including the following topics:
Introduction (0:00) Contemporary Care for Patients with Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation — Dr Langer (2:08) Evolving First-Line Treatment for Metastatic NSCLC with an EGFR Mutation — Dr Goldman (22:37) Biological Rationale for and Emerging Role of Antibody-Drug Conjugates in the Management of NSCLC with an EGFR Mutation — Dr Yu (43:23) Other Emerging Strategies for Relapsed Metastatic NSCLC with an EGFR Mutation — Dr Sabari (1:03:33) Current and Future Management of NSCLC with an EGFR Exon 20 Insertion Mutation — Dr Piotrowska (1:20:15) Management of Toxicities Associated with Available and Emerging Therapies for NSCLC with an EGFR Mutation — Dr Neal (1:38:44) CME information and select publications

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics:
Introduction (0:00) The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21) The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18) Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27) Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40) NCPD information and select publications

Featuring perspectives from Dr Petros Grivas, including the following topics:
Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27) Importance of collaborative care for patients with bladder cancer (42:02) Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57) Monitoring and management of T-DXd-associated side effects (1:00:47) Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32) Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22) Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer’s disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12) CME information and select publications